EMA signs off on Sanofi and GSK's BAR­DA-fund­ed Covid boost­er shot

The Eu­ro­pean Med­i­cines Agency on Thurs­day of­fered a pos­i­tive rec­om­men­da­tion for the first pro­tein-based ad­ju­vant­ed Covid-19 boost­er in Eu­rope, de­vel­oped by Sanofi and GSK.

The BAR­DA-fund­ed vac­cine, known as Vid­Pre­vtyn Be­ta, con­tains a ver­sion of the spike pro­tein found on the sur­face of the Be­ta vari­ant of the coro­n­avirus, and an ad­ju­vant to strength­en the im­mune re­sponse.

The EMA’s hu­man med­i­cines com­mit­tee said Thurs­day that there are suf­fi­cient­ly ro­bust da­ta on the qual­i­ty, safe­ty and im­muno­genic­i­ty of the vac­cine to rec­om­mend its mar­ket­ing au­tho­riza­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER